FAQ: Understanding Glioblastoma Remission Rates and Patient Information

What is glioblastoma and why is it concerning for patients?

Glioblastoma is the most deadly primary brain cancer that resists existing treatments, recurs in all patients, and has a relatively short average survival time of 14-18 months.

What percentage of glioblastoma patients experience remission lasting at least two years?

Only 25% of people diagnosed with glioblastoma experience remission lasting at least two years, indicating very low success rates for current treatments.

Why is understanding remission rates important for glioblastoma patients and caregivers?

Understanding remission rates enables patients and caregivers to have a clear picture of what to expect and helps guide them in making necessary decisions about treatment and care.

What companies are mentioned as working on glioblastoma treatments?

The content mentions CNS Pharmaceuticals Inc. (NASDAQ: CNSP) as one company working on glioblastoma treatments, with more information available in their newsroom at https://ibn.fm/CNSP.

Who published this information about glioblastoma remission rates?

This information was published by BioMedWire, a specialized communications platform focusing on biotechnology, biomedical sciences, and life sciences developments.

How can readers get more information about BioMedWire’s content?

Readers can visit https://www.BioMedWire.com for more information or receive SMS alerts by texting ‘Biotech’ to 888-902-4192 (U.S. Mobile Phones Only).

What makes glioblastoma particularly challenging to treat?

Glioblastoma is particularly challenging because it resists existing treatments and recurs in all patients, leading to very low remission rates and short survival times.

Where can investors find updates about CNS Pharmaceuticals mentioned in the article?

Investors can find the latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) in the company’s newsroom at https://ibn.fm/CNSP.